In early November, Pfizer and its German partner, BioNtech, released results of their ongoing trial for a COVID-19 vaccine, showing very positive early results of 90% efficacy rates. Shortly after, Moderna followed suit with similarly positive results from their COVID vaccine trial. In the midst of a second wave of increasing case counts and the communal weariness from ongoing (and increasing) restrictions and lockdowns, the good news couldn’t have come soon enough. Investors around the globe were quick to hitch their wagons to the idea of a vaccine-enabled return to gatherings, events, traditional business functions and economic activity.
To continue reading please click HERE
Investor sentiment improved in August, driven by hopes of rate cuts and extended trade truces.…
Trade tensions and cautious monetary policy continue to shape the global economic landscape. The U.S.…
Global equity markets rose in June as trade talks between the U.S., China, Canada and…
Trade talks, court rulings, and surprise tariff moves turned May into a geopolitical chess match.…
April's global markets faced turbulence due to trade and economic uncertainties. Discover how these factors…
Stay informed about the domestic and global impacts of U.S. tariffs amid economic unpredictability. Introduction…